Vanderbilt Study Shows the Pacifier Activated Lullaby (PAL®) combined with Mother’s Voice Improves Hospitalization and Feeding in Premature Babies
The study conducted by Vanderbilt was independent and unsponsored. Powers Device Technologies, Inc. had no involvement in this study nor affiliation with Vanderbilt
Delray Beach, FL– Powers Device Technologies Inc., announced that its Pacifier Activated Lullaby (PAL®) device was used in the landmark independent, randomized clinical trial performed in the Neonatal Intensive Care Unit (NICU) at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The study, published February 17, 2014 in the journal Pediatrics, found that premature babies who received interventional therapy combined with their mother’s voice with the Pacifier Activated Lullaby (PAL®) were able to have their feeding tubes removed a full week earlier. The babies also ate more efficiently and had shorter hospital stays than babies who did not receive the intervention.
In the study, when a baby sucked correctly on their PAL®, they were rewarded by hearing their mother singing a lullaby. If they stopped sucking, the music would stop. This relatively simple, short and reproducible intervention improves oral feeding skills in pre-term infants, including those with brain injury.
“Premature infants come into this world before they have a chance to achieve a major developmental milestone on which their survival depends – the ability to feed,” said Pat Palmer, President and CEO of Powers Device Technologies. “The PAL® with mother’s voice helps these babies to develop the strength and coordination to nurse effectively.”
The Vanderbilt study continues to validate the mounting independent, scientific evidence that preemies who use PAL®, an FDA-approved medical device, experience:
The PAL® system is commercially available through a network of medical distributors, and in some territories directly from the company. The PAL® system is presently being utilized in a number of hospitals for preemies with feeding issues and for the soothing of Neonatal Abstinence Syndrome (NAS) babies. The PAL® is also being utilized with individual recordings of the mother's voice singing lullabies to reinforce and promote proper sucking techniques for their babies. PAL® therapy is administered by therapists or nurses and qualifies for insurance reimbursement, utilizing existing CPT reimbursement codes.
About Powers Device Technologies, Inc.:
Powers Device Technologies, Inc., a Florida-based medical device company, develops therapeutic and diagnostic feedback sensor products to address the nutritional and distress tolerance (soothing) needs of preterm, full term, and critical care infants.
To find out more, visit www.powersdt.com.